Q2 Results: Higher R&D Expenses Impacted Performance, Says Biocon’s Shaw
A technician works at Biocon Ltd.’s cancer drug facility in Bangalore. (Photographer: Namas Bhojani/Bloomberg)

Q2 Results: Higher R&D Expenses Impacted Performance, Says Biocon’s Shaw

Biocon Ltd.’s operational metrics were affected by higher research and development spends and talent acquisition costs. That’s according to its Chairperson and Managing Director Kiran Mazumdar Shaw...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.